StockNews.AI
MGRM
StockNews.AI
160 days

CORRECTION: Monogram Technologies Reports Full Year 2024 Financial Results

1. MGRM submitted a response to the FDA's request regarding operational results. 2. A conference call is scheduled for March 12, 2025, to discuss business updates.

Earnings
-0.43%Current Return
VS
-1.33%S&P 500
$2.3203/12 07:19 PM EDTEvent Start
$2.3103/14 01:52 AM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

The positive progression in FDA interactions often leads to upward price movements. Historical cases, such as companies that received FDA clearance saw significant stock rallies.

How important is it?

The FDA's engagement is critical for MGRM's product road map, influencing both short-term and long-term stock price dynamics.

Why Short Term?

The imminent conference call could catalyze immediate investor interest and facilitate volatility around MGRM's stock price.

Related Companies

AAPLMSFTJNJ
This Press Release is Acting as a Correction to the Financial Tables in the Previous Release Completed all Supplemental Testing and has Submitted its Formal Response to the FDA's Additional Information Request (AIR) Management to Host Business Update Conference Call on Wednesday, March 12, 2025, at 4:30 p.m. Eastern Time AUSTIN, TEXAS / ACCESS Newswire / March 12, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the fourth quarter and year ended December 31, 2024.

Related News